Swiss National Bank lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 2.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 561,500 shares of the medical equipment provider's stock after selling 13,800 shares during the quarter. Swiss National Bank owned 0.28% of Zimmer Biomet worth $63,551,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Garde Capital Inc. acquired a new position in Zimmer Biomet in the 1st quarter worth $29,000. Menard Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $30,000. Washington Trust Advisors Inc. acquired a new stake in shares of Zimmer Biomet in the 1st quarter valued at about $30,000. Columbia River Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the 1st quarter valued at about $30,000. Finally, Accent Capital Management LLC acquired a new stake in shares of Zimmer Biomet in the 1st quarter valued at about $35,000. Institutional investors and hedge funds own 88.89% of the company's stock.
Zimmer Biomet Price Performance
Shares of Zimmer Biomet stock traded up $1.21 on Wednesday, hitting $103.03. The company had a trading volume of 1,254,277 shares, compared to its average volume of 2,089,097. The business has a 50-day simple moving average of $93.71 and a 200-day simple moving average of $99.59. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The company has a market cap of $20.41 billion, a PE ratio of 25.07, a PEG ratio of 2.28 and a beta of 0.68. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.22 and a 52 week high of $116.71.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. During the same period in the prior year, the business earned $2.01 earnings per share. The business's quarterly revenue was up 7.0% on a year-over-year basis. Research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.
Zimmer Biomet Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Thursday, July 31st. Investors of record on Thursday, June 26th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Thursday, June 26th. Zimmer Biomet's dividend payout ratio is 23.36%.
Wall Street Analyst Weigh In
ZBH has been the topic of a number of recent analyst reports. The Goldman Sachs Group cut their target price on shares of Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 6th. Stifel Nicolaus set a $115.00 target price on shares of Zimmer Biomet and gave the company a "buy" rating in a research note on Tuesday, May 6th. Royal Bank Of Canada increased their price objective on shares of Zimmer Biomet from $112.00 to $115.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Roth Capital reiterated a "buy" rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Finally, Canaccord Genuity Group dropped their price objective on shares of Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a research note on Monday, May 12th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Zimmer Biomet has a consensus rating of "Hold" and a consensus price target of $111.44.
Get Our Latest Report on ZBH
Insider Activity at Zimmer Biomet
In related news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the sale, the insider owned 20,424 shares in the company, valued at approximately $1,940,280. This represents a 4.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.70% of the company's stock.
Zimmer Biomet Company Profile
(
Free Report)
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
Read More

Before you consider Zimmer Biomet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.
While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.